[1]
|
European Parliament and Council Directive 2001/20/EC of 4 April 2001. OJ No L121/34 of 1 May 2001.
|
[2]
|
German Drug Law (2004) 12 Gesetz zur Anderung des Arzneimittelgesetzes. Bundesgesetzblatt Teil I Nummer 41.
|
[3]
|
Wingen, F.I. and Beinhauer, K.G. (2002) Development of clinical drug trial and the formal, legal and financial scope. Internist (German), 43, 463-468.
|
[4]
|
Thompson, D.F. (1993) Understanding financial conflicts of interest. The New England Journal of Medicine, 329, 573-576. doi:10.1056/NEJM199308193290812
|
[5]
|
Weber, L.J. (2006) Profits before people? Ethical standards and the marketing of prescription drugs. Indiana University Press, Bloomington.
|
[6]
|
Montori, V.M., Smieja, M. and Guyatt, G.H. (2000) Publication bias: A brief review for clinicians. Mayo Clinic Proceedings, 75, 1284-1288.
doi:10.4065/75.12.1284
|
[7]
|
Hirsch, L. (2004) Randomized clinical trials: What gets published, and when? Canadian Medical Association Journal, 170, 481-483.
|
[8]
|
Department of Health and Human Services (2004) Financial relationships and interests in research involving human subjects: Guidance for human subject protection. Federal Register Notices, 69, 26393.
|
[9]
|
De Angelis, C., Drazen, J.M., Frizelle, F.A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A.J., Schroeder, T.V., Sox, H.C. and Van Der Weyden, M.B. (2004) Clinical trial registration: A statement from the International Committee of Medical Journal editors. The New England Journal of Medicine, 351, 1250-1251.
|
[10]
|
Davidoff, F., DeAngelis, C.D., Drazen, J.M., Nicholis, M.G., Hoey, J., Hojgaard, L., Horton, R., Kotzin, S., Nylenna, M., Overbeke, A., Sox, H.C., Weyden, M. and Wilkes, M.S. (2001) Sponsorship, authorship and accountability. Canadian Medical Association Journal, 165, 786-788.
|
[11]
|
FDA (2006) Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees, 71FR 15421.
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf
|
[12]
|
Ahmer, S., Haider, I.J., Anderson, D. and Arya, P. (2006) Do pharmaceutical companies selectively report clinical trial data. Pakistan Journal of Medical Sciences, 22, 338-346.
|
[13]
|
House of Commons Health Committee (2005) The influence of the pharmaceutical industry. Fourth Report of Session, The Stationary Office Limited, London.
|
[14]
|
Ferner, R. (2005) The influence of big pharma. BMJ, 330, 855-856. doi:10.1136/bmj.330.7496.855
|
[15]
|
Turner, E.H., Matthews, A.M., Linardatos, E., Tell, R.A. and Rosenthal, R. (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. The New England Journal of Medicine, 358, 252-260.
doi:10.1056/NEJMsa065779
|
[16]
|
Melander, H., Ahlqvist-Rastad, J., Meijer, G. and Beermann, B. (2003) Evidence based medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ, 326, 1171-1173. doi:10.1136/bmj.326.7400.1171
|
[17]
|
Lee, K., Bachetti, P. and Sim, I. (2008) Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Medicine, 5, e191.
doi:10.1371/journal.pmed.0050191
|
[18]
|
Rising, K., Bachetti, P. and Bero, L. (2008) Reporting bias in drug trials submitted to the Food and Drug Administration: Review of publication and presentation. PLoS Medicine, 5, e217.
doi:10.1371/journal.pmed.0050217
|
[19]
|
Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W.D. and Lieb, K. (2010) The financing of drug trials by pharmaceutical companies and its consequences. Part 1: A qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Aerzteblatt International (German), 107, 279-285.
|
[20]
|
Schott, G., Pachl, H., Limbach, U., Gundert-Remy, U., Ludwig, W.D. and Lieb, K. (2010) The financing of drug trials by pharmaceutical companies and its consequences. Part 2: A qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. Deutsches Aerzteblatt International (German), 107, 295-301.
|
[21]
|
Kaiser, J. (2008) Making clinical data widely available. Science, 322, 217-218.
doi:10.1126/science.322.5899.217
|
[22]
|
PloS Medicine Editors (2008) Next stop, don’t block the doors: Opening up access to clinical trials results. PloS Medicine, 5, e160. doi:10.1371/journal.pmed.0050160
|
[23]
|
US Department of Health and Human Services (2007) Food and Drug Administration Amendments Act of 2007, P.L. 110-185.
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FoodandDrugAdministrationAmendmentsActof2007/FullTextofFDAAA Law/default.htm
|
[24]
|
Hirsch, L. (2008) Trial registration and results disclosure: Impact of US legislation on sponsors, investigators, and medical journal editors. Current Medical Research and Opinion, 24, 1683-1689.
doi:10.1185/03007990802114849
|
[25]
|
Mayor, S. (2005) Drug companies agree to make clinical trial results public. BMJ, 330, 109.
doi:10.1136/bmj.330.7483.109
|
[26]
|
PhRMA (2009) Revised clinical trial principles reinforce PhRMA’s commitment to transparency and strengthen authorship standards (press release), Washington DC.
http://www.phrma.org/sites/default/files/800/042009_clinical_trial_principles_final.pdf
|
[27]
|
Taylor, P. (2009) Emerging clinical trial locations— China. Market dynamics and regulatory environment. Business Insights Ltd, London.
|
[28]
|
Abdullahi vs. Pfizer Inc., 562 F.3d 163, 169 (2nd Cir. 2009).
|
[29]
|
European Commission (2005) Notice to Applicants. Questions & answers: Clinical trial documents, F2/BL D 2005, Brussels.
http://www.ct-toolkit.ac.uk/_db/_documents/ClinicalTrialQ&A_24-01-05.pdf
|
[30]
|
Department of Health, UK. (2004) EU Clinical Trials Directive: Sponsorship responsibilities in publicly funded trials. Medicines for human use (Clinical Trials) regulations 2004.
http://www.ct-toolkit.ac.uk/_db/_documents/sponsorship.pdf
|
[31]
|
Gainotti, S. and Petrini, C. (2010). Insurance policies for clinical trials in the United States and in some European countries. Journal of Clinical Research & Bioethics, 1, 1-8. doi:10.4172/2155-9627.1000001
|
[32]
|
Robinson, K. and Andrews, P.J. (2010) More trials and tribulations: The effect of the EU directive on clinical trials in intensive care and emergency medicine, five years after its implementation. Journal of Medical Ethics, 36, 322-325. doi:10.1136/jme.2009.035261
|
[33]
|
Meunier, F. and Lacombe, D. (2003) European Organisation for Research and Treatment of Cancer’s point of view. Lancet, 23, 663.
doi:10.1016/S0140-6736(03)14163-3
|
[34]
|
Ono, S. and Kodama, Y. (2000) Clinical trials and the new good clinical practice guideline in Japan. An economic perspective. Pharmacoeconomics, 18, 125-141.
doi:10.2165/00019053-200018020-00003
|
[35]
|
ICREL (2011) Report of project “Impact on Clinical Research of European Legislation”.
http://www.efgcp.be/icrel
|
[36]
|
Therasse, P., Eisenhauer, E.A., Buyse, M. (2006) Update in methodology and conduct of cancer clinical trials. European Journal of Cancer, 42, 1322-1330.
doi:10.1016/J.ejca.2006.02.006
|
[37]
|
Hemminki, A. and Kellokumpu-Lehtinen, P.L. (2006) Harmful impact of EU clinical trials directive. BMJ, 332, 501-502. doi:10.1136/bmj.332.7540.501
|
[38]
|
Morice, A.H. (2003) The death of academic clinical trials. Lancet, 361, 1568. doi:10.1016/S0140-6736(03)13211-4
|
[39]
|
Berendt, L., Hakansson, C., Bach, K.F., Dalhoff, K., Andreasen, P.B., Petersen, L.G,. Andersen, E. and Poulsen, H.E. (2008) Effect of European clinical trials directive on academic drug trials in Denmark: Retrospective study of applications to the Danish Medicines Agency, 1993-2006. BMJ, 336, 33-35. doi:10.1136/bmj.39401.470648.BE
|
[40]
|
Singer, E. (2007) Future of investigator initiated trials in EU academia. Basic & Clinical Pharmacology & Toxicology, 101, 11.
|
[41]
|
Gulland, A. (2009) Number of global clinical trials done in UK fell by two thirds after EU directive. BMJ, 338, 1052. doi:10.1136/bmj.b1052
|
[42]
|
The Commission of the European Communities (2005) Commission Directive 2005/28/EC of 8 April 2005. OJL, 91, 13-19.
|
[43]
|
European Forum for Good Clinical Practice (EFGCP) (2010) A road map initiative for clinical research in Europe. http://www.efgcp.be
|
[44]
|
Federation of the European Academics of Medicine (FEAM) (2011) Opportunities and challenges for reforming the EU clinical trials directive: An academic perspective: Statement.
http://www.leopoldina.org/fileadmin/user-upload/politik/Empfehlugen/FEAM/FEAM_Statement_EU-clinical-trials-directive_2010.pdf
|
[45]
|
European Forum for Good Clinical Practice (EFGCP) (2011) Conference report: Examining the value and the impact of the EU clinical trials directive-one year into the new European GCP reality.
http://www.efgcp.be/Downloads/EFGCP%20News%20Winter%202005.pdf
|
[46]
|
Demotes-Mainard, J. and Ohmann, C. (2005) European clinical research infrastructures network: Promoting harmonization and quality in European clinical research. Lancet, 365, 107-108. doi:10.1016/S0140-6736(05)17720-4
|
[47]
|
Demotes-Mainard, J., Chene, G., Libersa, C. and Pignon, J.P. (2005) Clinical research infrastructures and networks in France: Report on the French ECRIN workshop. Therapie, 60, 183-199. doi:10.2515/therapie:2005023
|
[48]
|
Bergmann, L., Berns, B., Dalgleish, A.G., von Euler, M. and Hecht, T.T. (2010) Investigator-initiated trials of targeted oncology agents: Why independent research is at risk? Annals of Oncology, 21, 1573-1578.
doi:10.1093/annonc/mdq018
|
[49]
|
Clumeck, N. and Katlama, C. (2004) Call for network of centers of excellence in clinical research in Europe. Lancet, 363, 901-902.
doi:10.1016/S0140-6736(04)15757-7
|
[50]
|
European Commission (2006) Guidance document on specific modalities for non-commercial clinical trials referred to in commission directive 2005/28/EC laying down the principles and detailed guidelines for good clinical practice.
http://ec.europa.eu/health/files/pharmacos/docs/doc2006/07_2006/guide_noncommercial_2006_07_27_en.pdf
|
[51]
|
Moniteur Belge, Belgium. Loi relative aux Experimentations sur la Personne Humaine; 7 May 2004.
http://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=fr&la=F&cn=2004050732&table_name=loi
|
[52]
|
Italian Medicines Agency (AIFA) (2010) Research and development working group. Feasibility and challenges of independent research on drugs: The Italian medicines agency experience. European Journal of Clinical Investigation, 40, 69-86.
doi:10.1111/j.1365-2362.2009.02226.x
|